Classifying Cytogenetics in Patients with Acute Myelogenous Leukemia in Complete Remission Undergoing Allogeneic Transplantation: A Center for International Blood and Marrow Transplant Research Study

被引：80

作者：

Armand, Philippe ^{[1
]}

Kim, Haesook T. ^{[2
]}

Zhang, Mei-Jie ^{[3
]}

Perez, Waleska S. ^{[4
]}

Dal Cin, Paola S. ^{[5
]}

Klumpp, Thomas R. ^{[6
]}

Waller, Edmund K. ^{[7
]}

Litzow, Mark R. ^{[8
]}

Liesveld, Jane L. ^{[9
]}

Lazarus, Hillard M. ^{[10
]}

Artz, Andrew S. ^{[11
]}

Gupta, Vikas ^{[12
]}

Savani, Bipin N. ^{[13
]}

McCarthy, Philip L. ^{[14
]}

Cahn, Jean-Yves ^{[15
]}

Schouten, Harry C. ^{[16
]}

Finke, Juergen ^{[17
]}

Ball, Edward D. ^{[18
]}

Aljurf, Mahmoud D. ^{[19
]}

Cutler, Corey S. ^{[20
]}

Rowe, Jacob M. ^{[21
]}

Antin, Joseph H. ^{[22
]}

Isola, Luis M. ^{[23
]}

Di Bartolomeo, Paolo ^{[24
]}

Camitta, Bruce M. ^{[25
]}

Miller, Alan M. ^{[26
]}

Cairo, Mitchell S. ^{[27
]}

Stockerl-Goldstein, Keith ^{[28
]}

Sierra, Jorge ^{[29
]}

Savoie, M. Lynn ^{[30
]}

Halter, Joerg ^{[31
]}

Stiff, Patrick J. ^{[32
]}

Nabhan, Chadi ^{[33
]}

Jakubowski, Ann A. ^{[34
]}

Bunjes, Donald W. ^{[35
]}

Petersdorf, Effie W. ^{[36
]}

Devine, Steven M. ^{[37
]}

Maziarz, Richard I. ^{[38
]}

Bornhauser, Martin ^{[39
]}

Lewis, Victor A. ^{[40
]}

Marks, David I. ^{[41
]}

Bredeson, Christopher N. ^{[42
]}

Soiffer, Robert J. ^{[43
]}

Weisdorf, Daniel J. ^{[44
]}

机构：

[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[2] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA

[3] Ctr Int Blood & Marrow Transplant Res, Dept Biostat, Milwaukee, WI USA

[4] Ctr Int Blood & Marrow Transplant Res, Dept Med, Milwaukee, WI USA

[5] Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA

[6] Temple Univ, Bone Marrow Transplant Program, Bone & Marrow Transplant Program, Philadelphia, PA 19122 USA

[7] Emory Univ Hosp, Dept Bone & Marrow Stem Cell Transplantat, Atlanta, GA 30322 USA

[8] Mayo Clin, Dept Hematol & Internal Med, Rochester, MN USA

[9] Univ Rochester, Strong Mem Hosp, Med Ctr, Dept Hematol & Oncol, Rochester, NY 14642 USA

[10] Univ Hosp Case Med Ctr, Dept Med Oncol, Cleveland, OH USA

[11] Univ Chicago Hosp, Dept Hematol & Oncol, Chicago, IL 60637 USA

[12] Princess Margaret Hosp, Dept Hematol, Toronto, ON M4X 1K9, Canada

[13] Vanderbilt Univ, Med Ctr, Dept Hematol & Oncol, Nashville, TN USA

[14] Roswell Pk Canc Inst, Dept Med, Buffalo, NY 14263 USA

[15] CHU Grenoble, Hosp A Michallon, Dept Hematol, F-38043 Grenoble, France

[16] Acad Ziekenhuis, Dept Med, Maastricht, Netherlands

[17] Univ Freiburg Klinikum, Dept Hematol & Oncol, Freiburg, Germany

[18] Univ Calif San Diego, Dept Med, Med Ctr, La Jolla, CA 92093 USA

[19] King Faisal Specialist Hosp & Res Ctr, Dept Hematol, Riyadh 11211, Saudi Arabia

[20] Dana Farber Canc Inst, Dept Med Oncol & Hematol Malignancies, Boston, MA 02115 USA

[21] Rambam Med Ctr, Dept Hematol, Haifa, Israel

[22] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[23] Mt Sinai Med Ctr, Dept Hematol & Oncol, New York, NY 10029 USA

[24] Osped Civile, BMT Ctr Pescara, Dept Hematol, Pescara, Italy

[25] Med Coll Wisconsin, Milwaukee, WI 53226 USA

[26] Baylor Univ, Med Ctr, Dept Oncol, Dallas, TX USA

[27] Columbia Univ, Med Ctr, Morgan Stanley Childrens Hosp New York Presbyteri, Dept Pediat Hematol & Oncol, New York, NY USA

[28] Washington Univ, Sch Med, Dept Bone Marrow Transplant, St Louis, MO USA

[29] Hosp Santa Creu & Sant Pau, Dept Hematol, Barcelona, Spain

[30] Tom Baker Canc Clin, Dept Med Oncol, Calgary, AB, Canada

[31] Univ Basel Hosp, Dept Internal Med, CH-4031 Basel, Switzerland

[32] Loyola Univ, Med Ctr, Dept Hematol & Oncol, Maywood, IL 60153 USA

[33] Advocate Lutheran Gen Hosp, Dept Hematol & Oncol, Park Ridge, IL USA

[34] Mem Sloan Kettering Canc Ctr, Dept Hematol Oncol, New York, NY 10021 USA

[35] Univ Ulm Klinikum, Dept Med, Ulm, Germany

[36] Fred Hutchinson Canc Res Ctr, Dept Oncol, Seattle, WA 98104 USA

[37] James Canc Ctr, Ohio State Med Ctr, Dept Blood & Marrow Transplant, Columbus, OH USA

[38] Oregon Hlth & Sci Univ, Dept Bone Marrow Transplant, Portland, OR 97201 USA

[39] Univ Klinikum Carl Gustav Carus, Dept Med, Dresden, Germany

[40] Alberta Childrens Prov Gen Hosp, Dept Hematol & Oncol, Calgary, AB T2T 5C7, Canada

[41] Bristol Childrens Hosp, Dept Hematol, Bristol, Avon, England

[42] Froedert Mem Lutheran Hosp, Dept Med, Milwaukee, WI USA

[43] Dana Farber Canc Inst, Dept Hematol Oncol, Boston, MA 02115 USA

[44] Univ Minnesota, Dept Med, Med Ctr, Minneapolis, MN 55455 USA

来源：

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2012年 / 18卷 / 02期

关键词：

AML; SCT; Karyotype; ACUTE MYELOID-LEUKEMIA; STEM-CELL TRANSPLANTATION; RETROSPECTIVE ANALYSIS; AML-10; TRIAL; DE-NOVO; SURVIVAL; THERAPY; CLASSIFICATION; RELAPSE; IMPACT;

D O I：

10.1016/j.bbmt.2011.07.024

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Cytogenetics play a major role in determining the prognosis of patients with acute myelogenous leukemia (AML). However, existing cytogenetics classifications were developed in chemotherapy-treated patients and might not be optimal for patients undergoing allogeneic hematopoietic cell transplantation (HCT). We studied 821 adult patients reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) who underwent HCT for AML in first or second complete remission between 1999 and 2004. We compared the ability of the 6 existing classifications to stratify patients by overall survival. We then defined a new scheme specifically applicable to patients undergoing HCT using this patient cohort. Under this scheme, inv(16) is favorable, a complex karyotype (4 or more abnormalities) is adverse, and all other classified abnormalities are intermediate in predicting survival after HCT (5-year overall survival, 64%, 18%, and 50%, respectively; P = .0001). This scheme stratifies patients into 3 groups with similar non-relapse mortality, but significantly different incidences of relapse, overall and leukemia-free survival. It applies to patients regardless of disease status (first or second complete remission), donor type (matched related or unrelated), or conditioning intensity (myeloablative or reduced intensity). This transplantation-specific classification could be adopted for prognostication purposes and to stratify patients with AML and karyotypic abnormalities entering HCT clinical trials.

引用

页码：280 / 288

页数：9

共 21 条

[1]

Multicenter validation study of a transplantation-specific cytogenetics grouping scheme for patients with myelodysplastic syndromes [J].